These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8267610)

  • 1. The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism.
    Bornheim LM; Kim KY; Chen B; Correia MA
    Biochem Biophys Res Commun; 1993 Dec; 197(2):740-6. PubMed ID: 8267610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsomal cytochrome P450-mediated liver and brain anandamide metabolism.
    Bornheim LM; Kim KY; Chen B; Correia MA
    Biochem Pharmacol; 1995 Aug; 50(5):677-86. PubMed ID: 7669071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides.
    Snider NT; Kornilov AM; Kent UM; Hollenberg PF
    J Pharmacol Exp Ther; 2007 May; 321(2):590-7. PubMed ID: 17272674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
    Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat.
    Costa B; Parolaro D; Colleoni M
    Eur J Pharmacol; 2002 Aug; 449(1-2):61-9. PubMed ID: 12163107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.
    Snider NT; Nast JA; Tesmer LA; Hollenberg PF
    Mol Pharmacol; 2009 Apr; 75(4):965-72. PubMed ID: 19171674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.
    Deutsch DG; Chin SA
    Biochem Pharmacol; 1993 Sep; 46(5):791-6. PubMed ID: 8373432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes.
    Devane WA; Axelrod J
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6698-701. PubMed ID: 8022836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
    Devane WA; Hanus L; Breuer A; Pertwee RG; Stevenson LA; Griffin G; Gibson D; Mandelbaum A; Etinger A; Mechoulam R
    Science; 1992 Dec; 258(5090):1946-9. PubMed ID: 1470919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anandamide amidohydrolase from porcine brain. Partial purification and characterization.
    Ueda N; Kurahashi Y; Yamamoto K; Yamamoto S
    Adv Exp Med Biol; 1997; 407():323-8. PubMed ID: 9321971
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.
    Fride E; Mechoulam R
    Eur J Pharmacol; 1993 Feb; 231(2):313-4. PubMed ID: 8384116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of an arachidonic acid hydroperoxide into epoxyhydroxy and trihydroxy fatty acids by liver microsomal cytochrome P-450.
    Weiss RH; Arnold JL; Estabrook RW
    Arch Biochem Biophys; 1987 Jan; 252(1):334-8. PubMed ID: 3813540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based inactivation of cytochrome P450 1A1 by N-aralkyl-1-aminobenzotriazoles in guinea pig kidney in vivo and in vitro: minimal effects on metabolism of arachidonic acid by renal P450-dependent monooxygenases.
    Knickle LC; Webb CD; House AA; Bend JR
    J Pharmacol Exp Ther; 1993 Nov; 267(2):758-64. PubMed ID: 8246152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid ligand-receptor signaling in the mouse uterus.
    Das SK; Paria BC; Chakraborty I; Dey SK
    Proc Natl Acad Sci U S A; 1995 May; 92(10):4332-6. PubMed ID: 7753807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of cannabidiol-mediated cytochrome P450 inactivation.
    Bornheim LM; Everhart ET; Li J; Correia MA
    Biochem Pharmacol; 1993 Mar; 45(6):1323-31. PubMed ID: 8466552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5.
    Lee AJ; Kosh JW; Conney AH; Zhu BT
    J Pharmacol Exp Ther; 2001 Aug; 298(2):420-32. PubMed ID: 11454902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipidomic metabolism analysis of the endogenous cannabinoid anandamide (N-arachidonylethanolamide).
    Placzek EA; Cooper BR; Placzek AT; Chester JA; Davisson VJ; Barker EL
    J Pharm Biomed Anal; 2010 Nov; 53(3):567-75. PubMed ID: 20417049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
    Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
    Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
    Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
    J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological effects in mice of anandamide and its related fatty acid ethanolamides, and enhancement of cataleptogenic effect of anandamide by phenylmethylsulfonyl fluoride.
    Watanabe K; Matsunaga T; Nakamura S; Kimura T; Ho IK; Yoshimura H; Yamamoto I
    Biol Pharm Bull; 1999 Apr; 22(4):366-70. PubMed ID: 10328555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.